What are the recommended dosing regimens for N‑acetylcysteine (NAC) for acetaminophen overdose, mucolytic therapy, and prevention of contrast‑induced nephropathy in adults?

N-Acetylcysteine Dosing Recommendations

For acetaminophen overdose, administer NAC immediately using the FDA-approved oral regimen: 140 mg/kg loading dose, followed by 70 mg/kg every 4 hours for 17 total doses, ideally initiated within 8-10 hours of ingestion to prevent hepatotoxicity and mortality. 1, 2

Acetaminophen Overdose Management

Timing is Critical for Survival

The evidence unequivocally demonstrates that early NAC administration dramatically reduces mortality and hepatotoxicity. When NAC is started within 8 hours of ingestion, severe hepatotoxicity occurs in only 2.9% of at-risk patients with zero mortality. This rises to 6.1% when treatment begins within 10 hours, and jumps to 26.4% when delayed beyond 10 hours 3. Delays beyond 16 hours result in hepatotoxicity rates of 62% 3.

Standard Dosing Protocol (FDA-Approved)

Oral NAC Regimen:

• Loading dose: 140 mg/kg orally
• Maintenance dose: 70 mg/kg every 4 hours for 17 additional doses (total 72 hours)
• Dilute 20% solution to 5% concentration using diet cola or soft drinks
• If vomiting occurs within 1 hour, repeat that dose 1, 2

Intravenous NAC Alternative: The three-bag IV regimen is also FDA-approved, though recent evidence suggests two-bag regimens reduce administration errors without compromising efficacy 4. However, the oral route remains the gold standard when tolerated.

Risk Stratification Using Rumack-Matthew Nomogram

Administer NAC immediately if:

• Any acetaminophen level plots in the "possible" or "probable" risk zones (above the treatment line)
• Ingestion occurred ≤24 hours ago, regardless of reported quantity
• Do not wait for lab results - start NAC empirically 3

Consider NAC even without clear risk stratification if:

• Detectable acetaminophen level with unknown ingestion time
• Elevated transaminases with suspected acetaminophen exposure
• Repeated supratherapeutic ingestions (>4g/day over multiple days)
• Extended-release formulation ingestion 3

Special Populations Requiring NAC

Level B Recommendation: Administer NAC to patients with hepatic failure thought to be due to acetaminophen, regardless of time since ingestion. This reduces mortality by 28% (from 80% to 52%) 3

Level C Recommendation: Administer NAC to patients with hepatotoxicity (elevated transaminases) and suspected acetaminophen overdose, including repeated supratherapeutic ingestions 3

Critical Pitfalls to Avoid

• Never delay NAC while awaiting acetaminophen levels - the 8-10 hour window is crucial
• Do not withhold NAC if activated charcoal was given - simply lavage first, as charcoal adsorbs NAC 1, 2
• For unknown ingestion times: Obtain second acetaminophen level if first is non-toxic but drawn <4 hours post-ingestion (peak may not yet be reached) 2
• Persistent vomiting: Consider duodenal intubation for NAC administration rather than abandoning treatment 1, 2

Massive Overdose Considerations

For extremely high acetaminophen concentrations (>300 mg/L on the nomogram), emerging evidence suggests standard NAC dosing may be insufficient. Consider escalating doses in consultation with toxicology, as hepatotoxicity rates increase with concentrations above the "300-line" 5. However, this remains an evolving area without formal guideline support.

---

Mucolytic Therapy

NAC is used as a mucolytic agent via inhalation at 10-20% concentration, typically 3-5 mL administered 3-4 times daily via nebulizer. This indication is distinct from overdose management and involves much lower systemic absorption. The evidence provided does not address specific mucolytic dosing protocols in detail 2.

---

Contrast-Induced Nephropathy Prevention

The Evidence is Equivocal and Disappointing

The most recent high-quality meta-analysis (2026) demonstrates that NAC does not prevent contrast-induced nephropathy, reduce need for hemodialysis, or decrease mortality 6. This contradicts earlier positive studies and represents the current best evidence.

Historical Dosing (No Longer Recommended Based on Latest Evidence)

Earlier studies suggested:

• Standard dose: 600 mg IV bolus pre-procedure, then 600 mg PO twice daily for 48 hours
• High dose: 1200 mg IV bolus pre-procedure, then 1200 mg PO twice daily for 48 hours 7

One 2006 study in primary angioplasty patients showed the high-dose regimen reduced contrast nephropathy from 33% (placebo) to 8% (high-dose NAC) with mortality reduction from 11% to 3% 7. A 2004 study similarly favored double-dose NAC for high contrast volumes 8.

Current Recommendation

Given the 2026 meta-analysis showing no benefit for oral or IV NAC in preventing contrast-induced nephropathy, routine prophylactic NAC cannot be recommended 6. Focus instead on adequate hydration and minimizing contrast volume. The earlier positive studies appear to have been contradicted by larger, more recent systematic reviews.

Exception for Emergency Settings

One 2012 study in elderly ED patients (mean age 79.6 years) showed single-dose 600 mg IV NAC before contrast CT reduced CIN from 14.6% to 7.5%, though without mortality benefit 9. This may represent a reasonable option when hydration is not feasible in emergency situations, but the overall evidence remains negative.